Dr. Savage “attended” the webinar held by the European Society of Sexual Medicine – Diabetes and Testosterone Deficiency

Professor A. Morgantaler from Boston, one of the world’s leading Andrologists presented 3 impressive studies about the effects of testosterone treatment in pre-diabetes and type 2 diabetes.

Conference 19th & 20th February 2021 and reports back on the following highlights –

First study an 8-year observational study by Lead Clinician Yasin, on pre-diabetics with starting testosterone levels < 12nnmol/l in the un-treated group 40% became full blown diabetics over the 8 year period, whereas those treated with long acting testosterone injection Nebido 1000 mg, none became diabetic.ERECTILE DYSFUNCTION

The second study was an 11-year observational study, lead by Lead Clinician Haider, this as of 356 men who had type 2 diabetes and starting testosterones <12 nnmol/l, in the group of patients who were treated with long acting Nebido 1000 mg there was a remission of diabetes in 34% of patients who had complete remission and were able to come off all diabetic medication.

The third study, Australian RCT study led by Professor Gary Wittert was a 2-year, large study of over 1000 patients, 88 in the treatment group having established type 2 diabetes and 355 pre-diabetes, there was a 40% reduction in the number of patients progressing to diabetes in comparison with those patients treated by intensive life style advice through the Weight Watchers programme.Testosterone deficiency in Type 2 diabetes

Screening for hypogonadism, there are now many leading endocrine and diabetes organisations which are suggesting screening all type 2 diabetics,those men with erectile dysfunction, obese men with waist size greater than 102cms. Check out Obesity Case Study

Remember, it has been found that 42% of diabetics have testosterone levels <12nnmol/l with symptoms of testosterone deficiency.

Hypogonadism is the commonest cause of osteoporosis and low trauma fracture in men, so all of these patients should be screened.

Metabolic syndrome doubles the risk of stroke and cardiovascular disease. It is the disease of the 21st century and will lead to an estimated prevalence of type 2 diabetes of 20% by 2030.

Many authors have stated that the type 2 diabetes epidemic will bankrupt the NHS.

The Leger Clinic